Highest-materiality recent filing
Breakthrough T1D awards grant for SAB-142 study in Stage 3 T1D beyond 100 days
Breakthrough T1D awarded grant to Dr. Michael Haller (U. Florida) for PRISE-hATG study of SAB-142 in Stage 3 T1D patients 100 days to 2 years from diagnosis.
Master Manufacturing Services Agreement executed April 28, 2026, with Emergent BioSolutions Canada Inc. for SAB-142.
All 4 T1D participants on SAB-142 2.5 mg/kg preserved C-peptide; 3 of 4 achieved super responder status with C-peptide above baseline at Day 120.
SAB Biotherapeutics prices $85M public offering of common stock and pre-funded warrants
Priced 19.3M shares at $3.85/share and pre-funded warrants for 2.75M shares at $3.8499 each.
SAB-142 Phase 1 data shows C-peptide preservation in established T1D patients at Day 120
T1D cohort (n=6): 4 treated with SAB-142 (2.5 mg/kg) showed no decline in C-peptide at Day 120; mean values increased above baseline.
SAB Bio appoints David Zaccardelli as Chair and Rita Jain as independent director
David Zaccardelli, Pharm.D., appointed Chair of the Board effective January 5, 2026; led Ohtuvayre launch at Verona Pharma.
SAB Biotherapeutics establishes new $75M ATM equity program via UBS, terminates prior $20M ATM
Entered sales agreement with UBS Securities for at-the-market offering of common stock up to $75 million aggregate offering price.
Shareholders approved increasing plan shares by 24,180,000 to 31,932,466 total; evergreen cap raised to 73,750,000 shares.
Gross proceeds of $175M from sale of Series B convertible preferred stock and warrants; conversion price $1.75 per common share.
Phase 1 trial of SAB-142 met primary safety and PD objectives; generally well-tolerated, no serum sickness or anti-drug antibodies at target dose.
SAB Bio completes Phase 1 healthy-volunteer enrollment; SAB-142 shows no serum sickness at 2.5 mg/kg
Phase 1 trial of SAB-142 for type 1 diabetes completed all planned healthy-volunteer cohorts; no serum sickness observed at target 2.5 mg/kg dose.
FDA clears IND for SAB Biotherapeutics' T1D therapy SAB-142 Phase 1 trial
FDA cleared IND for SAB-142, a human anti-thymocyte immunoglobulin for type 1 diabetes.
SAB Biotherapeutics reports FY2023 net loss $42.2M; cash $56.6M; funding into 2026
Net loss $42.2M for FY2023 versus $18.7M in 2022; cash and equivalents $56.6M as of Dec 31, 2023.
SAB Biotherapeutics regains Nasdaq minimum bid price compliance after reverse split
Received Nasdaq notice on Jan 23, 2024 confirming regained compliance with bid price rule.
SAB Biotherapeutics effects 1-for-10 reverse stock split to maintain Nasdaq listing
Reverse split effective 12:01 a.m. ET Jan 5, 2024; reduces outstanding shares from ~92.25M to ~9.225M.
SAB Biotherapeutics dosed first participants in Phase 1 trial of SAB-142 for Type 1 Diabetes
First-in-human Phase 1 trial dosed in Australia; double-blind, placebo-controlled, single-ascending dose design.
Shareholders approved amendment to increase authorized common stock from 490M to 800M shares on Nov 22, 2023.
SAB Biotherapeutics raises $67.154M in Series A-1 Preferred; restructures warrant tranches
Initially issued 7,500 Series A-1 Preferred shares for $7.5M on Oct 2, 2023.
Appoints Michael King as CFO with $450K salary and 850K share option grant
Michael King appointed CFO effective Oct 30, 2023; Russell Beyer ceased as CFO on Oct 27.
Initial closing of $7.5M from Series A-1 Preferred; potential total $130M via warrants and further tranches.
Auditor MHM declines re-election as SAB Biotherapeutics' independent auditor; going concern noted
MHM notified SAB Biotherapeutics on July 25, 2023 it will not stand for re-election as auditor for FY 2023.
SAB Biotherapeutics reports positive GLP tox study for SAB-142; IND submission planned
SAB-142 well tolerated in GLP tox study; NOAEL 10 mg/kg (highest dose).
Fast Track Designation granted by FDA for SAB-176, an anti-influenza polyclonal antibody therapy.
SAB Biotherapeutics reports positive Phase 3 results for SAB-185 in high-risk COVID-19 patients
66% of SAB-185 patients reached sustained symptom resolution by Day 28 vs 50% for REGEN-COV (p=0.010).
SAB Biotherapeutics receives FDA Breakthrough Therapy Designation for influenza therapeutic SAB-176
FDA granted Breakthrough Therapy Designation to SAB-176 for post-exposure prophylaxis of Type A/B influenza in high-risk patients.
Fast Track Designation granted for SAB-176, an investigational therapeutic for Type A and B influenza in high-risk patients, including those with antiviral-resistant strains.
SAB Biotherapeutics restates 2021 financials, delays 10-K; reports $15M cash, reduced burn
Restatement of 2021 financials due to misclassification of insurance financing; no net income impact, but prior statements should no longer be relied upon.
SAB Biotherapeutics settles Ladenburg lawsuit; issues warrant and agrees to pay $3.1M
Issued warrant for 300,000 shares at $0.5424 per share and paid $500K cash upfront.
SAB Biotherapeutics receives Nasdaq minimum bid price deficiency notice
Received Nasdaq notice on Jan 23, 2023; common stock bid price below $1.00 for 30 consecutive business days.
On July 26, 2024, Lucy To, 38, was appointed Chief Financial Officer of SAB Biotherapeutics, Inc., a Delaware corporation (“SAB BIO” or the “Company”), with a start date of August 12, 2024.
Mark Conley, who has been serving as Interim Chief Financial Officer since June 4, 2024, will reassume his prior position as the Company’s Vice President of Finance.
On May 30, 2024, Mark Conley, 62, was appointed Interim Chief Financial Officer of SAB Biotherapeutics, Inc., a Delaware corporation (the “Company”), effective June 4, 2024.
On May 26, 2024, Michael King, Jr., Chief Financial Officer of the Company, informed the Company that he will resign from his position with the Company, effective June 4, 2024, to pursue another opportunity.
On May 3, 2024, the Nominating and Corporate Governance Committee (the “ Committee ”) of the Board of Directors (the “ Board ”) of SAB Biotherapeutics, Inc., a Delaware corporation (the “ Company ”), recommended the appointment of, and the Board subsequently appointed, Dr. Jay S. Skyler to serve as a Class I director of the Company, effective as of May 3, 2024, and to serve until the Company’s 2025 annual meeting of stockholders or until Dr. Skyler’s successor is duly elected and qualified.
On January 30, 2024, Samuel J. Reich, age 49, the Executive Chairman of the Board of Directors (the “Board”) of SAB Biotherapeutics, Inc. (the “Company”), was appointed Chief Executive Officer of the Company, effective immediately.
recommended the appointment of, and the Board subsequently appointed, Ms. Helen Katherine Ellias to serve as a Class II director of the Company, effective as of November 20, 2023 until the Company’s 2026 annual meeting of stockholders
Michael King, age 62, was appointed Chief Financial Officer of SAB Biotherapeutics, Inc., a Delaware corporation (the “Company”), effective October 30, 2023.
Russell P. Beyer ceased to serve as Chief Financial Officer of the Company on October 27, 2023.
the Company’s Board of Directors approved the appointment of Andrew D. Moin, of Sessa Capital (Master), L.P., to the Company’s Board of Directors, effective upon the closing of the Offering.
the Board subsequently appointed, Mr. Erick Lucera to serve as a director of the Company, effective as of April 3, 2023
On December 31, 2021, Charles H. Randall, Chief Strategy Officer of SAB Biotherapeutics, Inc. (the “Company”), resigned.
Max materiality 0.85 · Median 0.60 · Most common event other_material